Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
COP$139.06+2.12(+1.55%)ConocoPhillips Q3 profit beats on higher prices, hikes dividend7:26:13 AM ETMETA$636.46+6.46(+1.03%)UPDATE 2-Meta sells first bonds in euros, raises €9 billion7:25:25 AM ETDTE$138.25+3.99(+2.97%)UPDATE 1-DTE Energy to sell its non-utility business for about $3 billion7:23:30 AM ETAAPL$352.60+3.09(+0.88%)Jim Cramer's Surprise Midterm Winner: Apple, Because Fewer Data Centers Could Mean Cheaper Memory7:19:09 AM ETMU$766.21-29.25(-3.68%)Could Buying Micron Stock Today Help Set You Up for Life?7:17:00 AM ETMSFT$556.10+0.30(+0.05%)Microsoft Is Executing an Irreproducible Balance-Sheet-Backed Infrastructure Pre-Sale at Scale7:15:58 AM ETAAPL$352.60+3.09(+0.88%)Apple Vs. Tesla: Low CapEx Only Matters if Non-Cyclical Cash Flows Come With It7:15:57 AM ETIREN$21.04-0.66(-3.04%)IREN is Only Fit for a Specific Investor Currently7:15:22 AM ETCOP$139.06+2.12(+1.55%)BRIEF-Conocophillips Q3 Adjusted EPS USD 3.27 Vs. IBES Estimate USD 2.977:13:20 AM ETMU$766.21-29.25(-3.68%)Micron Just Closed Below $800 for the First Time Since July7:12:48 AM ETCOP$139.06+2.12(+1.55%)ConocoPhillips beats profit estimates, boosts quarterly dividend7:11:13 AM ETCRWD$234.65-6.35(-2.63%)Too Late to Buy CrowdStrike Stock? Here's the 1 Thing to Watch.7:10:00 AM ETGOOG$291.12+3.82(+1.33%)These 6 Stocks Make Up a Big Share of the S&P 5007:09:00 AM ETCOP$139.06+2.12(+1.55%)UPDATE 1-ConocoPhillips beats profit estimates, boosts quarterly dividend7:07:07 AM ETLLY$1,428.98+10.84(+0.76%)Iconic California Brand, French Florist, Celebrates Grand Opening of First Indiana Location7:07:00 AM ETCVS$81.00+1.01(+1.26%)ProjectLeo, the First Private AI Health Platform to Declare Independence From Big Tech7:04:00 AM ETCOP$139.06+2.12(+1.55%)ConocoPhillips beats quarterly profit estimates7:01:40 AM ETCOP$139.06+2.12(+1.55%)ConocoPhillips announces third-quarter 2026 results and increases quarterly ordinary dividend by 11%7:00:05 AM ETPG$168.66+1.34(+0.80%)P&G to Webcast Presentation From P&G Investor Day 2026, November 197:00:03 AM ETV$440.17+3.58(+0.82%)Visa Forecasts U.S. Holiday Spending to Rise 4.5% as Consumers Keep the Holidays a Priority7:00:00 AM ETHD$360.20+4.76(+1.34%)Transom Appoints David Shields as Executive Vice President, Operations and Finance7:00:00 AM ETGS$937.89+9.61(+1.04%)RPT-BREAKINGVIEWS-Hong Kong summit exposes Wall Street AI confusion7:00:00 AM ETDTE$138.25+3.99(+2.97%)DTE Energy to sell DTE Vantage business for about $3 billion6:59:28 AM ETACN$268.00+3.73(+1.41%)Mondelēz International and Accenture Transform Order-to-Cash With AI6:59:02 AM ET

IRWD · NASDAQ

Ironwood Pharmaceuticals, Inc.

$4.14 +0.34 (+8.95%)

Company overview

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in Canada and the European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Market cap
$684M
Employees
253
Headquarters
Boston, MA
Website
ironwoodpharma.com
CEO
Thomas A. McCourt
Listed
February 3, 2010
P/E
6.51
Dividend yield
0.00%

Company financials

Revenue
$362M
Gross profit
$360M
Operating income
$202M
EBITDA
$205M
Net income
$102M
EPS
$0.64
Total assets
$435M
Total debt
$597M
Gross margin
99.62%
Net margin
28.26%
Earnings yield
15.36%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

3.083.544.014.484.95
IRWD 1D NASDAQ O3.61H3.80L3.58C3.80+0.29 (+8.43%)Vol1.95M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
IRWDIronwood Pharmaceuticals, Inc. Stock news BRIEF-Ironwood Pharmaceuticals Q3 Revenue USD 133.04 Million Reuters
IRWDIronwood Pharmaceuticals, Inc. Press release Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance Business Wire
IRWDIronwood Pharmaceuticals, Inc. Press release Crystal Pharmatech Completes ELDICO ED-1 Installation; Dedicated MicroED Now in Routine Service PR Newswire
IRWDIronwood Pharmaceuticals, Inc. Press release Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call Business Wire
IRWDIronwood Pharmaceuticals, Inc. Press release Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer Business Wire
IRWDIronwood Pharmaceuticals, Inc. Stock news Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? Zacks Investment Research
IRWDIronwood Pharmaceuticals, Inc. Stock news Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy Seeking Alpha
IRWDIronwood Pharmaceuticals, Inc. Stock news PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? Zacks Investment Research
IRWDIronwood Pharmaceuticals, Inc. Stock news Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy? Zacks Investment Research
IRWDIronwood Pharmaceuticals, Inc. Stock news 5 Small Drug Stocks Poised to Benefit From a Biotech Recovery Zacks Investment Research
IRWDIronwood Pharmaceuticals, Inc. Press release Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference Business Wire
IRWDIronwood Pharmaceuticals, Inc. Stock news Ironwood Pharmaceuticals: High Dependence On Its Next Trial Seeking Alpha
IRWDIronwood Pharmaceuticals, Inc. Stock news Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised Zacks Investment Research
IRWDIronwood Pharmaceuticals, Inc. Stock news Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript Seeking Alpha
IRWDIronwood Pharmaceuticals, Inc. Stock news Ironwood Pharmaceuticals Q2 Earnings Call Highlights MarketBeat
IRWDIronwood Pharmaceuticals, Inc. Stock news Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates Zacks Investment Research
IRWDIronwood Pharmaceuticals, Inc. Press release Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results Business Wire
IRWDIronwood Pharmaceuticals, Inc. Press release Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call Business Wire
IRWDIronwood Pharmaceuticals, Inc. Stock news Here's Why Ironwood Pharmaceuticals (IRWD) is a Strong Momentum Stock Zacks Investment Research
IRWDIronwood Pharmaceuticals, Inc. Press release Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients Business Wire
See more
FAQ

Questions about Ironwood Pharmaceuticals, Inc.

What does Ironwood Pharmaceuticals, Inc. do?
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in Canada and the European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
What is IRWD's market cap?
Ironwood Pharmaceuticals, Inc. (IRWD) is a listed stock with a live quote. The latest market cap on this page is $684M.
Where is Ironwood Pharmaceuticals, Inc. headquartered?
Ironwood Pharmaceuticals, Inc. is headquartered in Boston, MA.
How do I get IRWD news from the API?
Call GET /v1/news?tickers=IRWD. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does IRWD news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for IRWD, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the IRWD price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs